A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION

Authors
Category Primary study
JournalJOURNAL OF HEPATOLOGY
Year 2011
This article has no abstract
Epistemonikos ID: b0bc4adf1ee7ddbd7b722b5a2cf9d7e7fd0e64b2
First added on: Feb 04, 2025